Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

The HLA-A*24:02–restricted peptide vaccine targeting Wilms’ tumor 1 (WT1) (WT1 vaccine) is a promising therapeutic strategy for ovarian cancer; however, its efficacy varies among patients. In this study, we analyzed WT1-specific immune responses in patients with advanced or recurrent ovarian cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Sumiyuki, Morimoto, Soyoko, Oji, Yusuke, Morita, Satoshi, Shirakata, Toshiaki, Enomoto, Takayuki, Tsuboi, Akihiro, Ueda, Yutaka, Yoshino, Kiyoshi, Shouq, Alzaaqi, Kanegae, Mizuki, Ohno, Satoshi, Fujiki, Fumihiro, Nakajima, Hiroko, Nakae, Yoshiki, Nakata, Jun, Hosen, Naoki, Kumanogoh, Atsushi, Oka, Yoshihiro, Kimura, Tadashi, Sugiyama, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654282/
https://www.ncbi.nlm.nih.gov/pubmed/34874330
http://dx.doi.org/10.1097/CJI.0000000000000405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654282/
https://www.ncbi.nlm.nih.gov/pubmed/34874330
http://dx.doi.org/10.1097/CJI.0000000000000405

Ejemplares similares